Figure 4.

Incidence of selected adverse events, with events stratified by model‐predicted median C_max and AUC in study 1001 and study 1053. ^aMedians for cycle 2 day 1: Study 1001, C_max = 660.64 ng/mL; AUC = 2002 h ng/mL. For study 1053, C_max = 423.1 ng/mL; AUC = 652.8 h ng/mL. ^bMedians for cycle 1 day 1: For Study 1001, C_max = 286.74 ng/mL; AUC = 169.53 h ng/mL. For Study1053, C_max = 188.89 ng/mL; AUC = 122.03 h ng/mL.

AUC, area under the moxetumomab pasudotox concentration–time curve; CLS, capillary leak syndrome; C_max, maximum plasma drug concentration; Gr, grade; TEAE, treatment‐emergent adverse event